Author: Jane Edwards|| Date Published: August 28, 2020
The Trump administration has awarded Abbott Laboratories (NYSE: ABT) a potential $760M contract to provide 150M rapid COVID-19 diagnostics tests.
The Food and Drug Administration issued on Wednesday an emergency use authorization to the Abbott BinaxNOW COVID-19 Ag Card Point of Care SARS-CoV-2 test, which can provide results within 15 minutes without the need for instrumentation, the Department of Health and Human Services said Thursday.
The antigen test involves the use of nasal swabs and could be administered by medical staff in CLIA certified-environments.
“By strategically distributing 150 million of these tests to where they’re needed most, we can track the virus like never before and protect millions of Americans at risk in especially vulnerable situations,” said HHS Secretary Alex Azar.
The U.S. government plans to field the testing kits to schools and those “serving other special needs populations.”
AeroVironment has tapped Robert “Rob” Smith as executive vice president and chief operating officer. Smith’s appointment, which will become official April 13, underscores…
GreyNoise Intelligence has launched Command and Control Detection, a new intelligence module designed to identify active cyber compromises using outbound…
BigBear.ai has named Jo Ann Bjornson as chief human resources officer and Alex Thompson as chief corporate affairs officer. The new leadership appointments…
